Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
The Oncology Institute runs cancer care clinics and treats patients, earning money from insurers and government health programs for the care it provides.
The Oncology Institute is a cancer care company. It runs clinics where people with cancer go to see doctors, get chemotherapy and other drug treatments, and receive radiation therapy — the everyday, ongoing care that cancer patients need, rather than experimental research. It focuses on community settings, meaning ordinary neighborhoods and towns rather than giant downtown hospital centers, so patients can get treated closer to home.
The way it makes money is simple to describe but tricky to run. It gets paid by health insurance companies and government programs like Medicare for the treatments and visits it provides. In the American medical system, private insurers usually pay more than the government does, so a big part of the company's job is negotiating good rates with insurers and keeping patients coming back to its clinics instead of drifting to hospitals. It went public in 2021 by merging with a blank-check company, which is how it ended up trading on NASDAQ. Cancer care is a hard business to run well. Doctors are expensive, drugs cost a fortune, and a clinic only makes money when enough patients fill enough appointment slots. The Oncology Institute has grown quickly by buying up small independent oncology practices and folding them into its network, but that strategy has come with real strain. The company has reported losses and has had to work on its finances, and the stock has fallen a long way from its early days — a reminder that fast growth by acquisition can outrun the money coming in. What makes the business interesting is the bet underneath it: that cancer care can be delivered more cheaply and conveniently outside big hospitals, in clinics that specialize in it. If that bet works, the company becomes a valuable piece of the health care system. If costs stay high and insurers push back on prices, it becomes a tough, low-margin operation. Investors are essentially wagering on whether a smaller, focused cancer clinic can beat the hospital system at its own game.
Saved answer · last researched 21 Oct 2026
see a list of the most recent 300 searches below: